A Framework for Comprehensive Assessment of Medical Technologies: Defining Value in the New Health Care Ecosystem
Venture capital (VC) investment in medtech has declined over the past several years, placing the development of lifesaving innovations at risk. Many startup companies are struggling to make it out of the “valley of death,” the period between initial investment and creation of a commercially viable product. And while large medtech companies depend on a thriving external innovation ecosystem for acquisition targets and new sources of growth, many shy away from investing in early-stage, unproven technologies. This report explores how entrepreneurs, corporations, and investors can reinvigorate early-stage medtech innovation.